Shuttle Pharmaceuticals Files 8-K: Material Agreement & Equity Sales
Ticker: SHPH · Form: 8-K · Filed: Dec 29, 2025 · CIK: 1757499
| Field | Detail |
|---|---|
| Company | Shuttle Pharmaceuticals Holdings, Inc. (SHPH) |
| Form Type | 8-K |
| Filed Date | Dec 29, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.00001, $1.76 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, equity-sale, financials
TL;DR
Shuttle Pharma inked a big deal on Dec 23rd, filed equity sales & financials. 8-K out Dec 29th.
AI Summary
Shuttle Pharmaceuticals Holdings, Inc. entered into a material definitive agreement on December 23, 2025. The company also reported on unregistered sales of equity securities and filed financial statements and exhibits. The filing date was December 29, 2025.
Why It Matters
This 8-K filing indicates significant corporate activity, including a new material agreement and equity transactions, which could impact the company's financial position and future operations.
Risk Assessment
Risk Level: medium — The filing involves material definitive agreements and unregistered sales of equity, which can introduce financial and operational risks.
Key Players & Entities
- Shuttle Pharmaceuticals Holdings, Inc. (company) — Registrant
- December 23, 2025 (date) — Date of earliest event reported
- December 29, 2025 (date) — Filing date
- Delaware (jurisdiction) — State of incorporation
- Gaithersburg, MD (location) — Principal executive offices
FAQ
What type of material definitive agreement did Shuttle Pharmaceuticals Holdings, Inc. enter into?
The filing does not specify the nature of the material definitive agreement entered into on December 23, 2025.
What were the details of the unregistered sales of equity securities?
The filing mentions unregistered sales of equity securities but does not provide specific details regarding the number of shares, price, or purchasers.
What financial statements and exhibits were filed?
The filing indicates that financial statements and exhibits were filed, but their specific content is not detailed in the provided text.
What is the principal executive office address for Shuttle Pharmaceuticals Holdings, Inc.?
The principal executive offices are located at 401 Professional Drive, Suite 260, Gaithersburg, MD 20879.
What is the SEC file number for Shuttle Pharmaceuticals Holdings, Inc.?
The SEC file number for Shuttle Pharmaceuticals Holdings, Inc. is 001-41488.
Filing Stats: 820 words · 3 min read · ~3 pages · Grade level 11 · Accepted 2025-12-29 16:05:50
Key Financial Figures
- $0.00001 — ange on which registered Common Stock $0.00001 per share SHPH The Nasdaq Stock Mar
- $1.76 — ng date of the Agreement, at a value of $1.76 per share (which value was calculated i
Filing Documents
- form8-k.htm (8-K) — 43KB
- ex10-1.htm (EX-10.1) — 30KB
- 0001493152-25-029361.txt ( ) — 244KB
- shph-20251229.xsd (EX-101.SCH) — 3KB
- shph-20251229_lab.xml (EX-101.LAB) — 33KB
- shph-20251229_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SHUTTLE PHARMACEUTICALS HOLDINGS, INC. Dated: December 29, 2025 By: /s/ Christopher Cooper Name: Christopher Cooper Title: Chief Executive Officer